Similar companies
Income Statement ()
| Q4 '24 | QoQ |
|---|
Balance Sheet ()
| Q4 '24 | QoQ | |
|---|---|---|
| Total Assets | 18M | 17% |
| Total Liabilities | 22M | 31.3% |
| Shares Outstanding | 484M | 83961.9% |
Cash Flow ()
| Q4 '24 | QoQ |
|---|
Financial Highlights for Kazia Therapeutics in Q4 '24
Kazia Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.






